|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7620 EUR | -0.91% |
|
-1.30% | -20.62% |
| 05-22 | Transgene SA Announces Board Appointments | CI |
| 04-13 | Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer | CI |
Evolution of the Average Target: Transgene
Evolution of the Target Price: Transgene
Changes in Analyst Recommendations: Transgene
f234a748b8afb2b02040.81sTV7gS7uAtR6v6lM-coRoY8Sspuq-zQgqjKTTRdTA.gjMqFI0gr4h3JZqj57j1zlEqxEZx0-bCNXKTQ1WCWHTLCUZiwSqrsBwfnw~ee727608ab0248eeca689befce5b943b
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | - | - | +43.04% | |||
| +8.05% | |||||
| +46.39% | |||||
| +36.71% | |||||
| +101.96% | |||||
| +50.93% | |||||
| +42.87% | |||||
| -7.77% | |||||
| +31.9% | |||||
| -14.59% | |||||
| Average | +33.95% | |||||
| Weighted average by Cap. | +33.45% |
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.7690EUR
Average target price
1.100EUR
Spread / Average Target
+43.04%
High Price Target
1.100EUR
Spread / Highest target
+43.04%
Low Price Target
1.100EUR
Spread / Lowest Target
+43.04%
Analyst Consensus Detail
Consensus revision (last 18 months)
SellBuy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.7690EUR
Average target price
1.100EUR
Spread / Average Target
+43.04%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- TNG Stock
- Consensus Transgene
Select your edition
All financial news and data tailored to specific country editions
